Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment

Víctor A. Arrieta, Crismita Dmello, Daniel J. McGrail, Daniel J. Brat, Catalina Lee-Chang, Amy B. Heimberger, Dhan Chand, Roger Stupp, Adam M. Sonabend*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

38 Scopus citations


Immune checkpoint blockade (ICB) has revolutionized modern cancer therapy, arousing great interest in the neuro-oncology community. While several reports show that subsets of patients with glioma exhibit durable responses to immunotherapy, the efficacy of this treatment has not been observed for unselected patient populations, preventing its broad clinical implementation for gliomas and glioblastoma (GBM). To exploit the maximum therapeutic potential of ICB for patients with glioma, understanding the different aspects of glioma-related tumor immune responses is of critical importance. In this Review, we discuss contributing factors that distinguish subsets of patients with glioma who may benefit from ICB. Specifically, we discuss (a) the complex interaction between the tumor immune microenvironment and glioma cells as a potential influence on immunotherapy responses; (b) promising biomarkers for responses to immune checkpoint inhibitors; and (c) the potential contributions of peripheral immune cells to therapeutic responses.

Original languageEnglish (US)
Article numbere163447
JournalJournal of Clinical Investigation
Issue number2
StatePublished - Jan 17 2023

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment'. Together they form a unique fingerprint.

Cite this